Nextgen In-Vitro Diagnostics Private Limited, a active private limited company, was established on 24 April 2015 in New Delhi, Delhi, India. Engaging in ivf & maternity care centers within the professional, scientific and technical sector, it holds CIN: U33110DL2015PTC279481. Registered under ROC Roc Delhi. it is unlisted. It has an authorized capital of ₹4.05 Cr and a paid-up capital of ₹2.04 Cr.
It upholds a compliant status. Its leadership includes Sushil Mehta (Director), Devashish Ohri (Managing Director), Ashok Kumar Jain (Director). Past directors included Pravin Manjeshwar Kini, Vivek Chandra, Taracad Viswanathan Rajan. Its latest AGM occurred on 30 September 2024, with the balance sheet filed on 31 March 2024. It is based at C-1/59 Safdarjung Development Area, New Delhi, Delhi, 110016.
U33110DL2015PTC279481
279481
24 April 2015
₹4.05 Cr
₹2.04 Cr
Roc Delhi
Unlisted
Active
Explore comprehensive insights into Nextgen In-Vitro Diagnostics Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Sushil Mehta | Director | 12 Oct 2016 | Current |
| Devashish Ohri | Managing Director | 12 Aug 2024 | Current |
| Ashok Kumar Jain | Director | 02 Mar 2020 | Current |
| Pankaj Krishna | Director | 19 Dec 2023 | Current |
| Varun Chopra | Director | 24 Apr 2015 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Director | 05 Jun 2018 | Past |
| Pramod Abcsdd | Whole-Time Director | 31 Jul 2021 | Past |
| Pramod Abcsdd | Director | 05 Jun 2018 | Past |
| Pramod Abcsdd | Director | 05 Jun 2018 | Past |
| Pramod Abcsdd | Director | 30 Apr 2021 | Past |
| Pramod Abcsdd | Additional Director | 30 Dec 2016 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Nextgen In-Vitro Diagnostics Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
In 2023, Nextgen In-Vitro Diagnostics had a promoter holding of 80.33% and a public holding of 19.67%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
There are no open charges registered against the company as per our records.
Unlock and access historical data on people associated with Nextgen In-Vitro Diagnostics, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Gain comprehensive insights into the Deals and Valuation data of Nextgen In-Vitro Diagnostics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nextgen In-Vitro Diagnostics's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Progress on Nextgen In-Vitro Diagnostics Private Limited last Annual general meeting of members was held on 30 Sep 2024 as per latest MCA records. was documented.
The activity Devashish Ohri was appointed as a Managing Director was appointed as a Managing Director on 12 Aug 2024 & has been associated with this company since 1 year 3 months . was completed.
Progress on Nextgen In-Vitro Diagnostics Private Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Delhi. was documented.
Progress on Pankaj Krishna was appointed as a Director was appointed as a Director on 19 Dec 2023 & has been associated with this company since 1 year 11 months . was documented.
The activity Ashok Kumar Jain was appointed as a Director was appointed as a Director on 02 Mar 2020 & has been associated with this company since 5 years 8 months . was completed.
Sushil Mehta was appointed as a Director was appointed as a Director on 12 Oct 2016 & has been associated with this company since 9 years 1 month . was recorded as a recent event.
The CIN of Nextgen In-Vitro Diagnostics Private Limited is U33110DL2015PTC279481.
Nextgen In-Vitro Diagnostics Private Limited is headquartered at C-1/59 Safdarjung Development Area, New Delhi, Delhi, 110016.
Nextgen In-Vitro Diagnostics Private Limited was incorporated on 24 April 2015.
The current directors of Nextgen In-Vitro Diagnostics Private Limited are
The primary industry of Nextgen In-Vitro Diagnostics Private Limited is Professional, Scientific And Technical.
Nextgen In-Vitro Diagnostics Private Limited is unlisted.
The authorized capital of Nextgen In-Vitro Diagnostics Private Limited is ₹4.05 Cr, and the paid-up capital is ₹2.04 Cr.
The compliance status of Nextgen In-Vitro Diagnostics Private Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX